Edoardo Cignoli : Muscular Dystrophy Drug Suffers Setback

Sarepta Therapeutics said it would be delayed at least six months in seeking approval for its muscular-dystrophy drug after the FDA demanded more information because of concerns over the clinical-trial data.



via WSJ.com: US Business http://ift.tt/1wv5OB4